Suppr超能文献

脑室内溶栓不会增加脑出血后的出血周围水肿。

Intraventricular fibrinolysis does not increase perihemorrhagic edema after intracerebral hemorrhage.

机构信息

Department of Neurology, University of Erlangen-Nure, Schwabachanlage 6, 91054 Erlangen, Germany.

出版信息

Stroke. 2013 Feb;44(2):362-6. doi: 10.1161/STROKEAHA.112.673228. Epub 2013 Jan 10.

Abstract

BACKGROUND AND PURPOSE

Additional intraventricular hemorrhage leads to higher mortality and worse functional outcome after intracerebral hemorrhage (ICH). Intraventricular fibrinolysis (IVF) with recombinant tissue plasminogen activator (rtPA) is an emerging treatment strategy for such patients. However, experimental studies suggest that rtPA may exert proedematous effects and lead to increased perihemorrhagic edema (PHE) after ICH. We aimed to compare the course of PHE after ICH between patients who received IVF with rtPA and controls matched for ICH volume.

METHODS

Patients were identified retrospectively from our institutional ICH database. Sixty-four patients with ICH and intraventricular hemorrhage who were treated with IVF were compared with 64 controls, who did not receive IVF, matched for ICH volume. The course of PHE was assessed on computed tomography scans (day 1, days 2 and 3, days 4-6, 7-9, and 10-12) using a threshold-based semiautomatic volumetric algorithm. Relative PHE was calculated as a ratio of PHE volume and initial ICH volume.

RESULTS

The matching algorithm resulted in similar mean ICH volumes in both groups (20.01 ± 17.5 mL, IVF vs 20.08 ± 17.1 mL, control). Intraventricular hemorrhage volume was larger in the IVF group (26.8 ± 19.2 mL vs 9.2 ± 13.4 mL). The mean total rtPA dose used for IVF was 8 ± 6 mg. PHE increased over time in both groups until day 12. At all investigated time points, there was no significant difference in relative PHE between the IVF group and controls (F=0.39; P=0.844).

CONCLUSIONS

IVF with rtPA did not lead to a relevant increase in PHE after ICH. rtPA doses used in the current study seem to be safe regarding PHE.

摘要

背景与目的

脑出血(ICH)后继发脑室内出血会导致更高的死亡率和更差的功能预后。重组组织型纤溶酶原激活剂(rtPA)脑室内溶栓(IVF)是此类患者的一种新兴治疗策略。然而,实验研究表明,rtPA 可能发挥促水肿作用,并导致 ICH 后出血性周围水肿(PHE)增加。我们旨在比较接受 rtPA 脑室内溶栓治疗的患者与ICH 量匹配的对照组之间的 PHE 病程。

方法

我们从我们的机构 ICH 数据库中回顾性地确定了患者。将 64 例接受 IVF 治疗的 ICH 伴脑室内出血患者与未接受 IVF 治疗、ICH 量匹配的 64 例对照组进行比较。使用基于阈值的半自动容积算法在 CT 扫描上(第 1 天、第 2 天和第 3 天、第 4-6 天、第 7-9 天和第 10-12 天)评估 PHE 过程。相对 PHE 定义为 PHE 体积与初始 ICH 体积的比值。

结果

匹配算法导致两组的平均 ICH 体积相似(IVF 组 20.01 ± 17.5 mL,对照组 20.08 ± 17.1 mL)。IVF 组的脑室内出血体积较大(26.8 ± 19.2 mL 比 9.2 ± 13.4 mL)。IVF 中使用的平均总 rtPA 剂量为 8 ± 6 mg。两组的 PHE 均随时间增加,直到第 12 天。在所有研究的时间点,IVF 组与对照组之间的相对 PHE 无显著差异(F=0.39;P=0.844)。

结论

ICH 后 rtPA 脑室内溶栓并未导致 PHE 明显增加。本研究中使用的 rtPA 剂量在 PHE 方面似乎是安全的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验